ALTIMMUNE, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-12: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-12 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-03-17 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-17 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | During 2025, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. No stock o… | |
| 2026-03-17 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | During 2025, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. | |
| 2026-03-17 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-03-17 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-17 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. | |
| 2026-03-17 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-03-17 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Value of Initial Fixed $100 Average Investment Summary Summary Average Based on Compensation Compensation Compensation Compensation Total Ta… | |
| 2026-03-17 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (1) The PEO was Vipin Garg (CEO) for each of the years presented. The Non-PEO NEOs for each of the years presented were listed below: ● For 2025 – Christophe Arbet-Engels (CMO), M. Scot Roberts (CSO) and M. Scott Harris (former CMO) ● For 2024 – M. Scott Harris (CMO) and M. Scot Roberts (CSO) ● For … | |
| 2026-03-17 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | (3) In accordance with Item 402 (v) of Regulation S-K, the following adjustments were made to determine the CAP to our PEO during fiscal year 2025, which consisted solely of adjustments to the PEO’s equity awards: Compensation Actually Paid 2025 SCT – Total Compensation $ 8,026,590 Adjus… | |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInStockAwards; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.15M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInOptionAwards; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$4.81M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $1.85M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.77M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$312.07K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$2.11M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: IncrementalFairvalueFromExtensionOfOutstandingOptionExercisePeriod; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $2.07M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$6.24M |
| 2026-03-17 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | (5) In accordance with Item 402 (v) of Regulation S-K, the following adjustments were made to determine the average CAP to our Non-PEO NEOs during fiscal year 2025, which consisted solely of adjustments to the Non-PEO NEOs’ equity awards: Compensation Actually Paid 2025 SCT – Total Compens… | |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInStockAwards; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$489.37K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInOptionAwards; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.27M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.08M |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$413.02K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$153.81K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$285.97K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: IncrementalFairvalueFromExtensionOfOutstandingOptionExercisePeriod; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $105.92K |
| 2026-03-17 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.42M |
| 2026-03-17 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | ||
| 2026-03-17 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | ||
| 2026-03-06 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-06 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-06 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-06 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-06 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-06 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-06 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-06 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-06 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-08-15 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-08-15 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | During 2024, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. No stock o… | |
| 2025-08-15 DEF 14A | Award Timing Method | 2024-01-01..2024-12-31 | During 2024, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. No stock o… | |
| 2025-08-15 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | No | |
| 2025-08-15 DEF 14A | Award Timing Predetermined | 2024-01-01..2024-12-31 | Yes | |
| 2025-08-15 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | we did not time the disclosure of material nonpublic information for the purpose of affecting the value of such awards. | |
| 2025-08-15 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-08-15 DEF 14A | Pay versus Performance Table | 2024-01-01..2024-12-31 | Value of Initial Fixed $100 Average Investment Summary Summary Average Based on Compensation Compensation Compensation Compensation Total Ta… | |
| 2025-08-15 DEF 14A | Named Executive Officers Footnote | 2024-01-01..2024-12-31 | Value of Initial Fixed $100 Average Investment Summary Summary Average Based on Compensation Compensation Compensation Compensation Total Ta… | |
| 2025-08-15 DEF 14A | Adjustment To PEO Compensation Footnote | 2024-01-01..2024-12-31 | (3) In accordance with Item 402 (v) of Regulation S-K, the following adjustments were made to determine the CAP to our PEO during fiscal year 2024, which consisted solely of adjustments to the PEO’s equity awards: Compensation Actually Paid 2024 SCT – Total Compensation $ 6,090,462 Adjus… | |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInStockAwards; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$1.56M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInOptionAwards; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$3.54M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $3.89M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$1.52M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$915.68K |
| 2025-08-15 DEF 14A | Adjustment To Compensation | ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$3.64M |
| 2025-08-15 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2024-01-01..2024-12-31 | (5) In accordance with Item 402 (v) of Regulation S-K, the following adjustments were made to determine the average CAP to our Non-PEO NEOs during fiscal year 2024, which consisted solely of adjustments to the Non-PEO NEOs’ equity awards: Compensation Actually Paid 2024 SCT – Total Compens… | |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInStockAwards; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$541.95K |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardsInOptionAwards; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$1.23M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $1.35M |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$555.60K |
| 2025-08-15 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$336.90K |
| 2025-08-15 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$1.31M |
| 2025-08-15 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2024-01-01..2024-12-31 | ||
| 2025-08-15 DEF 14A | Compensation Actually Paid Vs Net Income | 2024-01-01..2024-12-31 | ||
| 2025-08-12 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-02-27 10-K | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-02-27 10-K | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | The Named Executive Officers are eligible to receive equity awards under the Altimmune, Inc. 2017 Omnibus Incentive Plan (as amended, the “ 2017 Plan ”). Awards under the 2017 Plan are intended to align the interests of the Named Executive Officers with those of our stockholders and to create a link… | |
| 2024-11-12 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-09-30 | No | |
| 2024-11-12 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-09-30 | No | |
| 2024-11-12 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-09-30 | No | |
| 2024-11-12 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-09-30 | No | |
| 2024-08-08 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-06-30 | No | |
| 2024-08-08 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-06-30 | No | |
| 2024-08-08 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-06-30 | No | |
| 2024-08-08 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-06-30 | No | |
| 2024-05-09 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-09 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-09 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-09 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-03-27 10-K | Material Terms Of Trading Arrangement | 2023-10-01..2023-12-31 | Item 9B. Other Information Insider Trading Arrangements On December 19, 2023, Dr. Vipin Garg, our President and Chief Executive Officer entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to… | |
| 2024-03-27 10-K | Non Rule10b51Arr Adopted | 2023-10-01..2023-12-31 | No | |
| 2024-03-27 10-K | Rule10b51Arr Terminated | 2023-10-01..2023-12-31 | No | |
| 2024-03-27 10-K | Non Rule10b51Arr Terminated | 2023-10-01..2023-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |